Vimal Mehta, BioXcel CEO
April 19, 2022 10:47 AM EDTUpdated 11:30 AM
Financing

On heels of psych drug ap­proval, BioX­cel dives head first in­to on­col­o­gy R&D with new cash in­fu­sion

Paul Schloesser

Associate Editor

Two weeks af­ter New Haven, CT biotech BioX­cel Ther­a­peu­tics won FDA ap­proval for the psy­chi­atric drug Igal­mi, the biotech is mak­ing a ma­jor new move …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times